UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
June 9, 2009
Valeant Pharmaceuticals International
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
|
|
1-11397
(Commission File Number)
|
|
33-0628076
(IRS Employer Identification No.) |
One Enterprise
Alisa Viejo, California 92656
(Address of Principal Executive Offices)
Registrants telephone number, including area code:
(949) 461-6000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 1.01 Entry into a Material Definitive Agreement
The information provided in Item 2.03 below is hereby incorporated herein by reference.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
On June 9, 2009, Valeant Pharmaceuticals International (the Company) completed its previously
announced note offering (the Offering) of $365 million principal amount of 8.375% senior notes
due 2016 (the Notes). The Notes were priced at 96.797% of the principal amount. The Notes were
sold in a private placement pursuant to a purchase agreement filed herewith and resold by the initial purchasers to qualified institutional buyers
pursuant to Rule 144A of the Securities Act of 1933, as amended (the Securities Act) and to
non-U.S. persons pursuant to Regulation S of the Securities Act. The Notes have not been registered
under the Securities Act or any state securities law and may not be offered or sold in the United States absent registration or
an applicable exemption from the registration requirements.
The Notes will mature on June 15, 2016 and will accrue interest at the rate of 8.375% per year.
Interest on the Notes will be payable semi-annually in arrears on each June 15 and December 15,
commencing on December 15, 2009. The Company may redeem some or all of the Notes at any time prior
to June 15, 2012 by paying a make-whole premium, plus accrued and unpaid interest, if any, to the
redemption date. At any time prior to June 15, 2012, the Company may use the net cash proceeds of
certain equity offerings of capital stock of the Company to redeem up to 35% of the principal
amount of the Notes at a redemption price equal to 108.375% of their principal amount plus accrued
and unpaid interest, plus liquidated damages, if any, to the redemption date; provided that at
least 65% of the aggregate principal amount of notes issued under the indenture described below
remain outstanding immediately after such redemption. At any time on or after June 15, 2012, the
Company may redeem some or all of the Notes by paying a redemption price expressed as a percentage
of the principal amount (104.188% if redeemed during the twelve-month period beginning on June 15,
2012, 102.094% if redeemed during the twelve-month period beginning on June 15, 2013, and 100% if
redeemed on or after June 15, 2014), plus accrued and unpaid
interest, plus liquidated damages, if
any, to the redemption date.
If the Company experiences a change of control, it may be required to offer to purchase the Notes
at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest, plus
liquidated damages, if any, to but excluding the repurchase date.
The Notes are senior obligations of the Company, and will be unconditionally guaranteed on a senior
basis by each of the Companys present and future U.S. subsidiaries that qualify as restricted
subsidiaries under the indenture described in the following paragraph.
The Notes have been issued under an indenture with The Bank of New York Mellon Trust Company, N.A.,
as trustee. The indenture governing the Notes contains covenants that will limit the ability of the
Company and the ability of its restricted subsidiaries to, among other things: incur additional
debt; pay dividends or make other distributions, repurchase capital stock, repurchase subordinated
debt and make certain investments; create liens; create restrictions on the payment of dividends
and other amounts to the Company from restricted subsidiaries; sell assets or merge or consolidate
with or into other companies; and engage in transactions with affiliates. If an event of default,
as specified in the indenture governing the Notes, shall occur and be continuing, either the
trustee or the holders of a specified percentage of the Notes may accelerate the maturity of all
the Notes. The covenants, events of default and acceleration rights described in this paragraph are
subject to important exceptions and qualifications, which are described in the indenture filed
herewith.
Under an exchange and registration rights agreement with the initial purchasers listed therein, the
Company is obligated, within 365 days after the issuance of
the Notes, to file with United States Securities
and Exchange Commission under the Securities Act a registration statement with respect to an offer
to exchange the Notes for new notes of the Company having terms substantially identical in all
material respects to the Notes (except that the exchange notes will not contain terms with respect
to transfer restrictions). If the Company is not able to effect this exchange offer, the Company
has agreed to use its reasonable best efforts to file, and cause to become effective, a shelf
registration statement relating to resales of the Notes and the Note guarantees. The Company will
be obligated to pay liquidated damages consisting of additional interest on the Notes if, within the periods specified in the
exchange and registration rights agreement, it does not file the exchange offer registration
statement or the shelf registration statement, have the registration statement
declared effective, consummate the exchange offer or have the shelf registration statement declared
effective, or if, after the shelf registration statement has been declared effective, such
registration statement thereafter ceases to be effective or useable (subject to certain exceptions)
in connection with resales of notes or exchange notes in accordance with and during the periods
specified in the exchange and registration rights agreements.
The descriptions set forth above are qualified in their entirety by the purchase agreement, the indenture and the exchange
and registration rights agreement governing the Notes filed herewith as exhibits. The schedules and
annexes to the exhibits attached hereto have been omitted. The Company hereby agrees to furnish
supplementally a copy of any omitted schedule or annex to the exhibits attached hereto to the
Securities and Exchange Commission upon its request.
Item 7.01 Regulation FD Disclosure.
Attached as Exhibit 99.4 hereto is summary historical and adjusted financial data of the Company
included in the confidential offering circular relating to the Offering.
The information disclosed under this Item 7.01, including Exhibit 99.4 hereto, is being furnished
and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, and shall not be deemed incorporated by reference into any filing made under the
Securities Act except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) |
|
Exhibits. |
|
99.1 |
|
Exchange and Registration Rights Agreement, dated as of June 9, 2009, by and among the
Company, Goldman, Sachs & Co. and UBS Securities LLC as Representative of the several Initial
Purchasers named therein and the Guarantors (as defined therein), relating to the 8.375%
Senior Notes due 2016. |
|
99.2 |
|
Indenture, dated as of June 9, 2009, by and among the Company, the Guarantors named therein
and The Bank of New York Mellon Trust Company, N.A., as Trustee, relating to the 8.375% Senior
Notes due 2016. |
|
99.3 |
|
Purchase Agreement, dated as of June 3, 2009, by and among the Company, the Purchasers named
in Schedule I thereto and the Guarantors (as defined therein), relating to the 8.375% Senior
Notes due 2016. |
|
99.4 |
|
Summary historical and adjusted financial data of the Company. |